HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The RUNX1-MECOM fusion gene, resulting from t(3;21) translocation, is a key driver of acute megakaryoblastic leukemia.
• RUNX1-MECOM recruits histone deacetylase (HDAC) to exert its oncogenic functions.
• Previous studies established a RUNX1-MECOM mouse model for leukemia research.

Purpose of the Study:

• To investigate the role of Angiopoietin 1 (Angpt1) and Tek in RUNX1-MECOM leukemia.
• To evaluate the therapeutic potential of histone deacetylase inhibitors (HDACi) in this leukemia model.

Main Methods:

• Quantitative RT-PCR arrays and protein confirmation for Angpt1 and Tek expression.
• Stimulation assays with Angpt1 to assess downstream signaling (Tek and Akt phosphorylation).
• In vitro and in vivo studies using HDAC inhibitors (trichostatin A and valproic acid) on leukemia cells and mice.

Main Results:

• RUNX1-MECOM leukemia cells showed elevated Angpt1 and Tek expression, forming a potential autocrine loop.
• HDAC inhibitors (TSA, VPA) downregulated Angpt1 and Tek, inhibited leukemia cell growth, induced cell cycle arrest, apoptosis, and partial megakaryocytic differentiation.
• Valproic acid (VPA) treatment extended survival in secondary transplanted mice.

Conclusions:

• HDAC inhibitors may counteract RUNX1-MECOM leukemia by disrupting the Angpt1-Tek autocrine loop.
• HDACi demonstrate therapeutic potential as a targeted treatment for RUNX1-MECOM-type leukemia.